Last updated on June 2018

PK and Safety Study of XARTEMIS XR (7.5 mg Oxycodone HCl/325 mg APAP) in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain


Brief description of study

Phase 4, multicenter, open-label, multiple-dose study of the pharmacokinetics (PK) and safety of XARTEMIS XR in postsurgical adolescent subjects aged 12 to 17 years with moderate to severe acute pain. The study will assess the safety of administering multiple doses of XARTEMIS XR in this population.

Clinical Study Identifier: NCT02508935

Contact Investigators or Research Sites near you

Start Over

Allison Ross, MD

Duke University Health Systems
Durham, NC United States

Miheala Visoiu, MD

University of Pittsburgh Medical Center, University of Pittsburgh Physicians
Pittsburgh, PA United States